Overview

MS-20 on Patients With Ulcerative Colitis(UC)

Status:
Not yet recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

This is a small pilot study of the fermented soybean extract MicrSoy-20(MS-20) to confirm its ability to improve UC severity with the treatment of standard therapies. The primary endpoint, structural alteration of gut microbiota during the trial will be analyzed. Secondary endpoints aim to observe the changes of partial Mayo score, patient response of medication of UC treatments, biomarker changes in blood, and safety after taking MS-20.

Phase:

N/A

Details

Lead Sponsor:

National Taiwan University Hospital

Collaborator:

Microbio Co Ltd